SG11201404979RA - Thermosensitive nanoparticle formulations and method of making the same - Google Patents

Thermosensitive nanoparticle formulations and method of making the same

Info

Publication number
SG11201404979RA
SG11201404979RA SG11201404979RA SG11201404979RA SG11201404979RA SG 11201404979R A SG11201404979R A SG 11201404979RA SG 11201404979R A SG11201404979R A SG 11201404979RA SG 11201404979R A SG11201404979R A SG 11201404979RA SG 11201404979R A SG11201404979R A SG 11201404979RA
Authority
SG
Singapore
Prior art keywords
making
same
nanoparticle formulations
thermosensitive
thermosensitive nanoparticle
Prior art date
Application number
SG11201404979RA
Other languages
English (en)
Inventor
Robert A Reed
Daishui Su
Original Assignee
Celsion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celsion Corp filed Critical Celsion Corp
Publication of SG11201404979RA publication Critical patent/SG11201404979RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201404979RA 2012-02-17 2013-02-15 Thermosensitive nanoparticle formulations and method of making the same SG11201404979RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600418P 2012-02-17 2012-02-17
PCT/US2013/026453 WO2013123407A1 (en) 2012-02-17 2013-02-15 Thermosensitive nanoparticle formulations and method of making the same

Publications (1)

Publication Number Publication Date
SG11201404979RA true SG11201404979RA (en) 2014-10-30

Family

ID=48984771

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404979RA SG11201404979RA (en) 2012-02-17 2013-02-15 Thermosensitive nanoparticle formulations and method of making the same

Country Status (16)

Country Link
US (2) US20130230457A1 (de)
EP (1) EP2814464B1 (de)
JP (3) JP2015507019A (de)
KR (1) KR102161271B1 (de)
CN (2) CN104203216A (de)
AR (1) AR090080A1 (de)
AU (1) AU2013221292A1 (de)
CA (1) CA2864469C (de)
ES (1) ES2773299T3 (de)
HK (1) HK1200733A1 (de)
MX (1) MX2014009827A (de)
PH (1) PH12014501866A1 (de)
RU (1) RU2014133467A (de)
SG (1) SG11201404979RA (de)
TW (2) TWI637754B (de)
WO (1) WO2013123407A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3291797B1 (de) * 2015-05-04 2020-09-02 Versantis AG Verfahren zur herstellung von transmembranen ph-gradienten-vesikeln
GB201509934D0 (en) * 2015-06-08 2015-07-22 King S College London Nanoparticles
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN105078892B (zh) * 2015-09-06 2018-05-01 重庆医科大学 阿苯达唑热敏脂质体的制备方法
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
IT1230505B (it) * 1988-10-11 1991-10-25 Sicor Spa Procedimento per la conversione della daunorubicina in doxorubicina.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4990397A (en) * 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
NZ519856A (en) * 2000-01-28 2004-03-26 Alza Corp Liposomes containing an entrapped compound in supersaturated solution
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
WO2005002546A1 (en) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Stabilized topotecan liposomal composition and methods
KR20060123341A (ko) * 2003-11-20 2006-12-01 데렉스 쎄라퓨틱스 인코포레이티드 친유성 아민 함유 약제를 포함하는 안정한 리포좀 조성물
WO2006051549A2 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
US20060127467A1 (en) * 2004-12-14 2006-06-15 Watkin Kenneth L Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods
TWI388344B (zh) * 2005-08-23 2013-03-11 Celsion Corp 儲存奈米微粒調合物之方法
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2010540498A (ja) * 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
WO2009059449A1 (en) 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
EP2219587A4 (de) * 2007-11-14 2012-11-21 Univ California Sterol-modifizierte amphiphile lipide
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
US9844656B2 (en) * 2010-03-01 2017-12-19 The Regents Of The University Of California Localization of agents at a target site with a composition and an energy source
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles

Also Published As

Publication number Publication date
JP2020050681A (ja) 2020-04-02
CA2864469C (en) 2020-07-07
AR090080A1 (es) 2014-10-15
KR102161271B1 (ko) 2020-09-29
CN106727329B (zh) 2020-11-03
EP2814464A4 (de) 2015-08-05
EP2814464B1 (de) 2019-12-18
EP2814464A1 (de) 2014-12-24
KR20140126381A (ko) 2014-10-30
PH12014501866A1 (en) 2014-11-17
ES2773299T3 (es) 2020-07-10
JP6824452B2 (ja) 2021-02-03
WO2013123407A1 (en) 2013-08-22
US20130230457A1 (en) 2013-09-05
US10251901B2 (en) 2019-04-09
MX2014009827A (es) 2014-09-22
JP2018058858A (ja) 2018-04-12
TWI684463B (zh) 2020-02-11
TW201345565A (zh) 2013-11-16
HK1200733A1 (en) 2015-08-14
US20170080003A1 (en) 2017-03-23
CN104203216A (zh) 2014-12-10
AU2013221292A1 (en) 2014-09-11
CA2864469A1 (en) 2013-08-22
TW201841622A (zh) 2018-12-01
TWI637754B (zh) 2018-10-11
JP2015507019A (ja) 2015-03-05
RU2014133467A (ru) 2016-04-10
CN106727329A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
EP2852381A4 (de) Lipidnanopartikelzusammensetzungen und verfahren zur herstellung und verfahren zur verwendung davon
AP2014008172A0 (en) Nanocomposite and method of making the same
IL237156A0 (en) Microcapsule preparation and methods
HK1209079A1 (en) Catalytic forms and formulations
ZA201602510B (en) Strigolactone formulations and uses thereof
HK1208604A1 (en) Oral care implement and method of forming the same
HK1200733A1 (en) Thermosensitive nanoparticle formulations and method of making the same
SG11201405221PA (en) Catheter die and method of fabricating the same
HK1210714A1 (en) Antibody formulations and uses thereof
HK1211862A1 (en) Nanoparticle formulation
GB201503017D0 (en) Method and system for the production of nanoparticles
SG11201404728VA (en) Nanoparticle paste formulations and methods for production and use thereof
SG2013081724A (en) Sensor and method of controlling the same
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
SG11201405941QA (en) Article and method of making the same
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
PL2922698T3 (pl) Okno termochromowe oraz sposób jego wytwarzania
HK1175159A1 (en) Graphite block and the preparation method thereof
HK1212247A1 (en) Metadichol liquid and gel nanoparticle formulations metadichol
EP2909285A4 (de) Geliermittel und verwendungsverfahren dafür
SG11201500474PA (en) Nutriculture member and nutriculture method
HK1176343A1 (en) Modified grapheme and preparation method thereof
EP2837624A4 (de) 4-substituent-2-hydroxylmorpholin-3-on und herstellungsverfahren dafür
HK1199411A1 (en) Nano-emulsion composition and method for producing the same
PL2743282T3 (pl) Produkt kondensacji melaminy z aldehydem i sposób jego otrzymywania